US FDA Would See Cash Windfall In COVID-19 Relief Bill
Executive Summary
The $500m in additional funds would support pandemic-related activities, potentially for additional staff or technology upgrades.
You may also be interested in...
Drug Manufacturers Beg US FDA To Inspect Facilities, But Still Find Difficulties
As agency implements testing program for its staff, sponsors are drawing up protocols to ensure inspector safety and forwarding them to FDA, but still can’t trigger an inspection.
US FDA COVID Funds Move Forward In Congress, No Strings Attached
Amendment to require one-firth of the money be devoted to therapeutic review was defeated by the House Energy and Commerce Committee.
Medicaid Rebate Reform: A Sign Of Minimal Drug Pricing Threats Or A Warning Of More To Come?
House Democrats push to remove the current limit on Medicaid rebates in upcoming COVID-19 relief package would likely leave many drug companies unscathed, but some expect bigger ticket drug pricing items will soon be on the agenda.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: